EXELIXIS INC (EXEL) Stock Fundamental Analysis
USA - NASDAQ:EXEL - US30161Q1040 - Common Stock
41.35 USD
+0.15 (+0.36%)
41.45 USD
+0.1 (+0.24%)
Taking everything into account, EXEL scores 8 out of 10 in our fundamental rating. EXEL was compared to 536 industry peers in the Biotechnology industry. EXEL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: EXEL is growing strongly while it also seems undervalued. This makes EXEL very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year EXEL was profitable.
EXEL had a positive operating cash flow in the past year.
EXEL had positive earnings in each of the past 5 years.
EXEL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 22.49%, EXEL belongs to the top of the industry, outperforming 97.20% of the companies in the same industry.
EXEL has a Return On Equity of 29.62%. This is amongst the best in the industry. EXEL outperforms 97.39% of its industry peers.
Looking at the Return On Invested Capital, with a value of 25.22%, EXEL belongs to the top of the industry, outperforming 98.13% of the companies in the same industry.
EXEL had an Average Return On Invested Capital over the past 3 years of 10.78%. This is significantly below the industry average of 16.17%.
The last Return On Invested Capital (25.22%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| ROIC | 25.22% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
EXEL's Profit Margin of 27.01% is amongst the best of the industry. EXEL outperforms 96.08% of its industry peers.
EXEL's Profit Margin has declined in the last couple of years.
EXEL has a Operating Margin of 33.71%. This is amongst the best in the industry. EXEL outperforms 97.76% of its industry peers.
EXEL's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 96.59%, EXEL belongs to the best of the industry, outperforming 95.90% of the companies in the same industry.
EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.71% | ||
| PM (TTM) | 27.01% | ||
| GM | 96.59% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EXEL is creating value.
The number of shares outstanding for EXEL has been reduced compared to 1 year ago.
EXEL has less shares outstanding than it did 5 years ago.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 12.35 indicates that EXEL is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.35, EXEL belongs to the top of the industry, outperforming 87.87% of the companies in the same industry.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.35 |
ROIC/WACC2.52
WACC9.99%
2.3 Liquidity
EXEL has a Current Ratio of 3.51. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.51, EXEL is in line with its industry, outperforming 41.23% of the companies in the same industry.
A Quick Ratio of 3.44 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Quick ratio (3.44) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 67.74% over the past year.
The Earnings Per Share has been growing by 12.65% on average over the past years. This is quite good.
Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 10.73% in the last year.
Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 17.51% on average per year.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
3.2 Future
Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 22.20% on average per year.
EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.31% yearly.
EPS Next Y30.7%
EPS Next 2Y25.58%
EPS Next 3Y26.34%
EPS Next 5Y22.2%
Revenue Next Year7.25%
Revenue Next 2Y9.86%
Revenue Next 3Y11.39%
Revenue Next 5Y10.31%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.88, the valuation of EXEL can be described as rather expensive.
Based on the Price/Earnings ratio, EXEL is valued cheaper than 94.78% of the companies in the same industry.
When comparing the Price/Earnings ratio of EXEL to the average of the S&P500 Index (27.86), we can say EXEL is valued slightly cheaper.
EXEL is valuated correctly with a Price/Forward Earnings ratio of 14.17.
EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 95.52% of the companies in the same industry.
EXEL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.29, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.88 | ||
| Fwd PE | 14.17 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 95.52% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, EXEL is valued cheaply inside the industry as 96.83% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.76 | ||
| EV/EBITDA | 12.38 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
EXEL's earnings are expected to grow with 26.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.65
PEG (5Y)1.57
EPS Next 2Y25.58%
EPS Next 3Y26.34%
5. Dividend
5.1 Amount
No dividends for EXEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
41.35
+0.15 (+0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.89%
Inst Owner Change-0.45%
Ins Owners2.23%
Ins Owner Change10.58%
Market Cap11.13B
Analysts77.69
Price Target45.28 (9.5%)
Short Float %6.68%
Short Ratio5.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)-1.36%
PT rev (3m)7.44%
EPS NQ rev (1m)1.47%
EPS NQ rev (3m)2.65%
EPS NY rev (1m)2.3%
EPS NY rev (3m)5.74%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.88 | ||
| Fwd PE | 14.17 | ||
| P/S | 4.99 | ||
| P/FCF | 14.76 | ||
| P/OCF | 14.42 | ||
| P/B | 5.47 | ||
| P/tB | 5.65 | ||
| EV/EBITDA | 12.38 |
EPS(TTM)2.08
EY5.03%
EPS(NY)2.92
Fwd EY7.06%
FCF(TTM)2.8
FCFY6.77%
OCF(TTM)2.87
OCFY6.94%
SpS8.28
BVpS7.55
TBVpS7.32
PEG (NY)0.65
PEG (5Y)1.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| ROCE | 32.1% | ||
| ROIC | 25.22% | ||
| ROICexc | 38.09% | ||
| ROICexgc | 39.72% | ||
| OM | 33.71% | ||
| PM (TTM) | 27.01% | ||
| GM | 96.59% | ||
| FCFM | 33.81% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 60.32% | ||
| Cap/Sales | 0.81% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.79% | ||
| Profit Quality | 125.2% | ||
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 12.35 |
F-Score8
WACC9.99%
ROIC/WACC2.52
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y30.7%
EPS Next 2Y25.58%
EPS Next 3Y26.34%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.25%
Revenue Next 2Y9.86%
Revenue Next 3Y11.39%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year41.83%
EBIT Next 3Y24.19%
EBIT Next 5Y1.16%
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%